Elagolix free acid | CAS#834153-87-6 | GnRH Antagonist

MedKoo Cat#: 330137 | Name: Elagolix

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Elagolix, also known as NBI56418 and ABT-620, is a Gonadotropin-Releasing Hormone (GnRH) Antagonist. Elagolix inhibits gonadatropin releasing hormone (GnRH) receptors in the pituitary gland and ultimately reduces circulating sex hormone levels. Elagolix is believed to have its effect by altering the level of pituitary GnRH suppression and, as a result, titrating circulating estrogen levels. Elagolix was approved in 2018.

Chemical Structure

Elagolix

CAS#834153-87-6 (free acid)

Theoretical Analysis

MedKoo Cat#: 330137

Name: Elagolix

CAS#: 834153-87-6 (free acid)

Chemical Formula: C32H30F5N3O5

Exact Mass: 631.2106

Molecular Weight: 631.60

Elemental Analysis: C, 60.85; H, 4.79; F, 15.04; N, 6.65; O, 12.67

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 350.00	2 Weeks
50mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

834153-87-6 (free acid) 832720-36-2 (sodium)

Synonym

NBI56418; NBI-56418; NBI 56418; ABT-620; ABT 620; ABT620; Elagolix; Orilissa; (R)-Elagolix;

IUPAC/Chemical Name

(R)-4-((2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl)amino)butanoic acid

InChi Key

HEAUOKZIVMZVQL-VWLOTQADSA-N

InChi Code

InChI=1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)/t25-/m0/s1

SMILES Code

O=C(O)CCCN[C@H](C1=CC=CC=C1)CN(C(N(CC2=C(C(F)(F)F)C=CC=C2F)C(C)=C3C4=CC=CC(OC)=C4F)=O)C3=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 631.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Shebley M, Polepally AR, Nader A, Ng JW, Winzenborg I, Klein CE, Noertersheuser P, Gibbs MA, Mostafa NM. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis. Clin Pharmacokinet. 2019 Nov 21. doi: 10.1007/s40262-019-00840-7. [Epub ahead of print] Review. PubMed PMID: 31749075. 2: Neri M, Melis GB, Giancane E, Vallerino V, Pilloni M, Piras B, Loddo A, Paoletti AM, Mais V. Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data. Int J Womens Health. 2019 Oct 22;11:535-546. doi: 10.2147/IJWH.S185023. eCollection 2019. Review. PubMed PMID: 31695514; PubMed Central PMCID: PMC6815212. 3: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548061/ PubMed PMID: 31643392. 4: Rolla E. Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment. F1000Res. 2019 Apr 23;8. pii: F1000 Faculty Rev-529. doi: 10.12688/f1000research.14817.1. eCollection 2019. Review. PubMed PMID: 31069056; PubMed Central PMCID: PMC6480968. 5: Barra F, Scala C, Ferrero S. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain. Drugs Today (Barc). 2019 Apr;55(4):237-246. doi: 10.1358/dot.2019.55.4.2930713. Review. PubMed PMID: 31050692. 6: Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G. Uterine fibroids: an update on current and emerging medical treatment options. Ther Clin Risk Manag. 2019 Jan 23;15:157-178. doi: 10.2147/TCRM.S147318. eCollection 2019. Review. PubMed PMID: 30774352; PubMed Central PMCID: PMC6350833. 7: Elagolix (Orilissa)--an oral GnRH antagonist for endometriosis pain. Med Lett Drugs Ther. 2018 Sep 24;60(1556):158-160. Review. PubMed PMID: 30383729. 8: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK525496/ PubMed PMID: 30222288. 9: Lamb YN. Elagolix: First Global Approval. Drugs. 2018 Sep;78(14):1501-1508. doi: 10.1007/s40265-018-0977-4. Review. Erratum in: Drugs. 2018 Nov 15;:. PubMed PMID: 30194661; PubMed Central PMCID: PMC6244606. 10: Ferrero S, Barra F, Leone Roberti Maggiore U. Current and Emerging Therapeutics for the Management of Endometriosis. Drugs. 2018 Jul;78(10):995-1012. doi: 10.1007/s40265-018-0928-0. Review. PubMed PMID: 29946962. 11: Taylor HS. Use of Elagolix in Gynaecology. J Obstet Gynaecol Can. 2018 Jul;40(7):931-934. doi: 10.1016/j.jogc.2018.01.004. Review. PubMed PMID: 29921430. 12: Barra F, Scala C, Mais V, Guerriero S, Ferrero S. Investigational drugs for the treatment of endometriosis, an update on recent developments. Expert Opin Investig Drugs. 2018 May;27(5):445-458. doi: 10.1080/13543784.2018.1471135. Epub 2018 May 17. Review. PubMed PMID: 29708812. 13: Legendre G, Delbos L, Hudon E, Chabbert-Buffet N, Geoffron S, Sauvan M, Fernandez H, Bouet PE, Descamps P. [New medical treatments for painful endometriosis: CNGOF-HAS Endometriosis Guidelines]. Gynecol Obstet Fertil Senol. 2018 Mar;46(3):256-263. doi: 10.1016/j.gofs.2018.02.009. Epub 2018 Mar 9. Review. French. PubMed PMID: 29530558. 14: Ciebiera M, Łukaszuk K, Męczekalski B, Ciebiera M, Wojtyła C, Słabuszewska-Jóźwiak A, Jakiel G. Alternative Oral Agents in Prophylaxis and Therapy of Uterine Fibroids-An Up-to-Date Review. Int J Mol Sci. 2017 Dec 1;18(12). pii: E2586. doi: 10.3390/ijms18122586. Review. PubMed PMID: 29194370; PubMed Central PMCID: PMC5751189. 15: Perricos A, Wenzl R. Efficacy of elagolix in the treatment of endometriosis. Expert Opin Pharmacother. 2017 Sep;18(13):1391-1397. doi: 10.1080/14656566.2017.1359258. Epub 2017 Jul 28. Review. PubMed PMID: 28737050. 16: Goenka L, George M, Sen M. A peek into the drug development scenario of endometriosis - A systematic review. Biomed Pharmacother. 2017 Jun;90:575-585. doi: 10.1016/j.biopha.2017.03.092. Epub 2017 Apr 10. Review. PubMed PMID: 28407578. 17: Alessandro P, Luigi N, Felice S, Maria PA, Benedetto MG, Stefano A. Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature. Arch Gynecol Obstet. 2017 Apr;295(4):827-832. doi: 10.1007/s00404-017-4328-6. Epub 2017 Mar 3. Review. PubMed PMID: 28255765. 18: Melis GB, Neri M, Corda V, Malune ME, Piras B, Pirarba S, Guerriero S, Orrù M, D'Alterio MN, Angioni S, Paoletti AM. Overview of elagolix for the treatment of endometriosis. Expert Opin Drug Metab Toxicol. 2016 May;12(5):581-8. doi: 10.1517/17425255.2016.1171316. Review. PubMed PMID: 27021205. 19: Soliman AM, Yang H, Du EX, Kelley C, Winkel C. The direct and indirect costs associated with endometriosis: a systematic literature review. Hum Reprod. 2016 Apr;31(4):712-22. doi: 10.1093/humrep/dev335. Epub 2016 Feb 6. Review. PubMed PMID: 26851604. 20: Leone Roberti Maggiore U, Ferrero S. An overview of early drug development for endometriosis. Expert Opin Investig Drugs. 2016;25(2):227-47. doi: 10.1517/13543784.2016.1126579. Epub 2015 Dec 19. Review. PubMed PMID: 26619754.